Tobira, Regado merged business will focus on NASH therapies
This article was originally published in Scrip
Executive Summary
Tobira Therapeutics, which last year discarded IPO plans, will merge its business with publically traded Regado Biosciences in an all-stock transaction, creating one company focused on the development of novel treatments for liver and inflammatory diseases.